QuantX opens dosing in first-in-human QX-4533 trial, target undisclosed
The Phase 1 study moved to Recruiting with no mechanism, target, or indication named, leaving safety data due December 25, 2026 as the only near-term signal.
Executive Summary
- NCT07678463 moved from Not yet recruiting to Recruiting on July 7, 2026, six days after the trial's July 1 registration and five days after dosing was set to start, confirming QuantX Biosciences began enrolling healthy volunteers into its first disclosed clinical trial of QX-4533 NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463.
- The registry lists QX-4533's target, mechanism of action, and indication as unknown, which means this update cannot be read against any named competitor or disease landscape.
- Both primary endpoints are safety measures, clinically significant lab abnormalities and treatment-emergent adverse events, not efficacy signals, so the December 25, 2026 primary completion date will resolve tolerability, not whether the drug works NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463.
- AppliedXL has no probability call on record for this catalyst, and the readout-date forecasting tool returned no prediction row for this trial, leaving investors without a quantified expectation to test against [AXL-MODEL].
What changed
NCT07678463 registered on ClinicalTrials.gov on July 1, 2026, with a trial start date of July 2, and its status moved to Recruiting on July 7 NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463. That is a five-day gap between the planned start and the confirmed recruiting status, consistent with a study that opened its single Australian site on schedule. The trial's protocol-stability tracker shows zero amendments and a total-change-events count of zero since the initial filing, earning a Stable label. For a Phase 1 study six days into its life, that stability is unremarkable: there has not yet been time for the protocol to drift.
What the trial will test
The study is a single- and multiple-ascending-dose escalation with a food-effect component, enrolling 90 healthy adults aged 18 to 55 at one site in Australia NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463. Both primary endpoints are safety measures: the number of participants with clinically significant changes in clinical laboratory parameters, and the number with treatment-emergent adverse events, each tracked through Day 9 for single-dose participants and Day 23 for multiple-dose participants NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463. Secondary endpoints cover standard pharmacokinetic parameters, including clearance, volume of distribution, AUC, Cmax, half-life, and Tmax, plus ECG monitoring NCT07678463A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy ParticipantsNCT07678463. This is a tolerability and exposure study. It is not designed to, and cannot, establish whether QX-4533 works against any disease.
The disclosure gap
The registry lists QX-4533's target, mechanism of action, and indication as "__UNKNOWN__," and a direct mechanism-classification lookup returned no match. A competitive-trials search for QX-4533 returned exactly one result, the trial itself, with zero head-to-head comparator trials identified. AppliedXL's competitive-context model marks this asset as not first-in-class, but for a different reason than novelty: the basis is "lead_target_unknown," meaning the model cannot classify the compound's competitive position because the target has not been disclosed. Until QuantX names the mechanism, no reader can assess whether QX-4533 competes in a crowded field or an empty one.
Sponsor and pipeline context
QuantX Biosciences' entire disclosed clinical pipeline consists of this single Recruiting trial. No FDA approval history exists for QX-4533, and no regulatory designations, such as Fast Track, Breakthrough Therapy, or Orphan Drug status, have been recorded for the compound or the sponsor. That leaves this Phase 1 study as the sole evidence base for the program. The landscape-risk assessment labels the setting "challenging" with a score of 50 out of 100, but the underlying signals are populated with placeholder values because no competitive density, historical outcome, or sponsor-experience data exists to fill them. The label should be read as a data gap, not a measured difficulty.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.